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Abstract
Background: Perturbation of neuronal excitability contributes to migraine. Neurosteroids modulate the activity of γ-
aminobutyric acid A and N-methyl-d-aspartate receptors, and might be involved in the pathogenesis of migraine. Here,
we measured plasma levels of four neurosteroids, i.e., allopregnanolone, epiallopregnanolone, dehydroepiandrosterone
and deydroepiandrosterone sulfate, in patients affected by episodic migraine, chronic migraine, or cluster headache.
Methods: Nineteen female patients affected by episodic migraine, 51 female patients affected by chronic migraine,
and 18 male patients affected by cluster headache were recruited to the study. Sex- and age-matched healthy control
subjects (31 females and 16 males) were also recruited. Patients were clinically characterized by using validated
questionnaires. Plasma neurosteroid levels were measured by liquid chromatography-tandem mass spectrometry.
Results: We found disease-specific changes in neurosteroid levels in our study groups. For example, allopregnanolone
levels were significantly increased in episodic migraine and chronic migraine patients than in control subjects, whereas
they were reduced in patients affected by cluster headache. Dehydroepiandrosterone and dehydroepiandrosterone
sulfate levels were reduced in patients affected by chronic migraine, but did not change in patients affected by cluster
headache.
Conclusion: We have shown for the first time that large and disease-specific changes in circulating neurosteroid levels
are associated with chronic headache disorders, raising the interesting possibility that fluctuations of neurosteroids at
their site of action might shape the natural course of migraine and cluster headache. Whether the observed changes in
neurosteroids are genetically determined or rather result from exposure to environmental or intrinsic stressors is
unknown. This might also be matter for further investigation because stress is a known triggering factor for headache
attacks in both migraineurs and cluster headache patients.
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Introduction
Migraine is a chronic disease with relevant clinical and
social implications. The recently released results of the
Global Burden of Disease initiative reveal that migraine
is the fifth leading chronic disease on the planet, being
more prevalent than diabetes [1, 2]. Also, migraine nega-
tively influences quality of life, and is the fourth leading
disease per number of years lived with disability [1, 2].
These figures highlight the existing gaps in the prevent-
ive and symptomatic treatment of migraine.
Among other predisposing factors, the pathogenesis of
migraine and cluster headache appears to be related to
an impaired control of neuronal excitability [3]. Hence,
unraveling the trans-synaptic and/or intracellular mech-
anisms that alter neuronal firing in migraine and cluster
headache may provide new insights into the pathophysi-
ology of these disorders and pave the way to novel thera-
peutic interventions. Neurosteroids are endogenous
steroids synthesized in the central nervous system (CNS)
that modulate neuronal excitability by interacting with
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either γ-aminobutyric acid A or N-methyl-d-aspartate
receptors [4–6]. Neurosteroids are synthesized in glial
cells from cholesterol or other precursors via progressive
reduction of the A-ring of the steroid molecule [4]. Most
of the current research on neurosteroids focuses on
allopregnanolone (AP), epiallopregnanolone (EAP),
dehydroepiandrosterone (DHEA), and DHEA sulfate
(DHEAS). AP-like neurosteroids are potent positive
allosteric modulators as well as direct activators of both
synaptic and extrasynaptic γ-aminobutyric acid A recep-
tors, and, therefore, they can maximally enhance synap-
tic phasic inhibition and extrasynaptic tonic inhibition
[4]. In contrast, DHEA and DHEAS are weak antago-
nists of γ-aminobutyric acid A receptor and agonists of
N-methyl-d-aspartate receptors [7]. Thus, allopregnano-
lone and DHEA/DHEAS display opposite effects on
neuronal excitability. The clinical relevance of neuroster-
oids is exemplified by their potential role in the patho-
physiology of epilepsy [8, 9]. An imbalance between
excitatory and inhibitory neurotransmission leading to a
hyperactivation of N-methyl-d-aspartate receptors is
considered as a key event in the development of
migraneous aura and in mechanisms of nociceptive
sensitization underlying the central component of migra-
neous pain [10, 11]. Owing to their mechanisms of action,
neurosteroids might participate to the pathophysiology of
migraine particularly under conditions associated with
changes in the peripheral production of progesterone and
other neurosteroid precursors (e.g., the pre-menstraul
period). The association between serum γ-aminobutyric
acid levels and the clinical characteristics of migraine sug-
gests a causal link between changes in γ-aminobutyric acid
mediated neurotransmission and the pathophysiology of
migraine [12]. However, whether neurosteroids are part of
this link remains undetermined.
The aim of our study was to measure for the first time
circulating levels of neurosteroids in patients with
ICHD3-beta confirmed diagnosis [13] of episodic or
chronic migraine (EM, CM), medication overuse head-
ache (MOH) and cluster headache (CH), and to explore
possible associations with their clinical characteristics.
Migraine and cluster headache are complex and multi-
faceted clinical diseases, whose conceptual framework
has been recently organized by the International Classifi-
cation of Headache Disorders 3rd Edition beta classifica-
tion [13]. In particular, migraine is considered as a
primary headache and patients are diagnosed as having
episodic (EM) or chronic migraine (CM) according to
well established clinical parameters [13]. In the Inter-
national Classification of Headache Disorders 3rd
Edition beta classification, medication-overuse headache
(MOH) is considered within secondary headaches and
thus it is independent from migraine [14]. However, it
has been recently proposed that MOH should be more
correctly considered a complication of CM, if not even
in some cases its natural evolution as CM plus medica-
tion overuse (CM +MO) [15, 16]. Cluster headache
(CH) is also a primary headache, but it is not classified
together with migraine rather as a trigeminal autonomic
cephalalgia [13].
Materials and methods
The protocol has been devised as a cross-sectional study.
It complies with the rules set by the Declaration of
Helsinki and subsequent amendments, and has been
approved by the Azienda Ospedaliero-Universitaria
Sant’Andrea Ethics Committee. The study has been
carried out between February and December 2017.
Patients
Patients of both sexes, aging 18–80 years and referring to
the Headache Unit at Azienda Ospedaliera-Universitaria
S. Andrea, Rome, were recruited for the study. Patients
were cognitively able to sign the informed consent, and
received the diagnosis of EM, or CM, or CM +MO, or
CH according to the International Classification of Head-
ache Disorders 3rd Edition -beta criteria [13]. Patients
with cancer, liver failure, renal failure or recent adminis-
tration of benzodiazepines were excluded from the study.
Sex- and age-matched healthy subjects were recruited as
controls.
Study design
After signing the informed consent, patients were
enrolled and the following information collected and
registered: age, sex, education, comorbidities, actual drug
therapy, the presence of a concurrent migraine/headache
attack, number of attacks/month, day of the menstrual
cycle (women only). Then, validated psychometric and
functional questionnaires were provided. In particular,
patients were asked to fill the Beck Depression Inventory
(BDI), the Migraine Disability Assessment Test (MIDAS;
only migraine patients), the Headache Impact test
(HIT-6), and the Self-rating Anxiety Scale (SAS). BDI is
a validated questionnaire for quantifying the severity of
depression. MIDAS provides a precise assessment of
migraine-induced disability. HIT-6 measures the impact
of headache on daily activities. SAS provides a quantita-
tive assessment of anxiety.
Biochemistry
After signing informed consent, blood sample was col-
lected, and immediately centrifuged. This occurred in the
morning, between 8 AM and 9 AM. Aliquots of plasma
were separated and kept at − 20 °C until further analysis.
Circulating levels of AP (ng/mL), EAP (ng/mL), DHEA
(ng/mL) and DHEAS (μg/mL) were measured by liquid
chromatography-tandem mass spectrometry (LC-MS/
Koverech et al. The Journal of Headache and Pain           (2019) 20:61 Page 2 of 7
MS), using the protocol developed and validated at our
institution and previously described [17]. Briefly, the
analytes were first derivatized with 2-hydrazinopyridine
and extracted from plasma using solid phase extraction.
Then, the compounds were separated and detected by
LC-MS/MS. A mobile phase of formic acid (0.1%) in
water and methanol through a gradient of composition
and a flow rate of 0.3/mL/min was used since we dem-
onstrated that results in good separations of the analytes
[17]. By using this protocol, linear responses in wide
range of concentrations and limits of quantification ran-
ging from 10 (DHEAS) to 40 pg/mL (DHEA) are ob-
tained in < 9min [17].
Statistical analysis
Results were statistically analysed by Student’s t test and
by one-way ANOVA and Fisher’s LSD as a post-hoc test
where appropriate. Possible associations between con-
tinuous variables were assessed by the Pearson’s correl-
ation test. Data are presented as means ± S.D.
Results
Screening and enrolment procedures are illustrated by
the CONSORT flow diagram in Fig. 1.
Considering the imbalanced gender distribution within
groups, and the potential role of female sex hormones as
precursors of neurosteroids [18], we decided to consider
only female patients for EM, CM and MOH, and only male
patients for CH. Also, as previously mentioned [15, 16],
MOH can be considered as a complication or even as the
natural evolution of CM. Therefore, patients with MOH
were merged into the CM group.
The control groups included 31 female healthy
individuals and 16 male healthy individuals. Patients’
and controls’ characteristics are reported in Table 1.
Episodic migraine
Plasma neurosteroid levels fell within the expected range
in all our patients and controls (e.g., 3–10 nM
corresponding approximately to 1–3.7 ng/ml of AP) [19].
AP and EAP levels were largely increased in patients
affected by EM, whereas DHEA levels were reduced by
> 40% (Table 2). No changes in DHEAS levels and in the
ratio between AP and EAP were found in patients
affected by EM with respect to healthy controls (1.9 ±
0.9 vs 1.8 ± 1.2; p = n.s.). Knowing that the ovarian cycle
has a strong impact on neurosteroid synthesis [16], we
also examined AP, EAP, DHEA, and DHEAS levels in
pre- and post-menopausal patients and healthy controls.
Differences in AP, EAP, and DHEAS levels between EM
patients and controls were maintained when subjects
were stratified according to their menopausal status. In
addition, no changes in neurosteroid levels were found
between pre- and post-menopausal EM patients.
No significant associations were found between blood
neurosteroids and BDI, SAS, HIT-6 and MIDAS scores,
and educational level in EM patients and controls.
Chronic migraine (including medication-overuse)
Circulating levels of neurosteroids in CM patients are
shown in Table 3. Similarly to EM patients, CM patients
showed large increases in AP levels, whereas EAP levels
did not change, and levels of both DHEA and DHEAS
were reduced. A direct comparison of AP, DHEA, and
DHEAS levels between patients affected by EM and CM
is shown in Table 4. Interestingly, DHEA and DHEAS
levels were significantly lower in CM patients with
respect to EM patients, whereas AP levels did not differ
between the two groups (Table 4). Thus, neurosteroids
behaved differently in EM and CM patients, as
compared to their respective controls. At least in CM
patients, changes in neurosteroid levels were unaffected
by the hormonal status, as shown by a subgroup analysis
in patients examined before and after menopause, or in
fertile patients examined in the follicular and luteal
phases of the ovarian cycle (data not shown). Thus, it
appears that migraine itself rather than fluctuations in
Fig. 1 CONSORT flow diagram of the study (M=males; F=female; decl. = declined)
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ovarian hormones, is the main driver of neurosteroid
changes in CM patients.
In the overall population of CM patients neurosteroid
levels also did no change when blood samples were
collected during a migraine attack or in the interictal
period (Table 5). However, changes were found when pa-
tients affected by CM+MO were isolated from the overall
population of CM patients according to the ICDH3-beta
diagnostic criteria. In these patients, AP levels were lower
during the headache attack (0.9 ± 0.2 ng/mL vs 1.1 ± 0.2
ng/mL, respectively; p < 0.05), whereas in the remaining
CM patients, DHEAS levels were higher during the attack
(1.8 ± 1.4 μg/mL vs 0.9 ± 0.6 μg/mL, respectively; p < 0.05).
AP and EAP are known to differentially regulate
γ-aminobutyric acid A receptors, with AP activating and
EAP inhibiting receptor function, respectively [20].
Hence, we measured the AP/EAP ratio as a surrogate
marker of the cumulative effects of these neurosteroids
on γ-aminobutyric acid mediated transmission. The AP/
EAP ratio was higher In the overall population of CM
patients with respect to healty control (3.0 ± 1.7 vs 1.8 ±
1.2, respectively; p < 0.01), whether or not blood samples
were collected during the headache attack or in the
interictal period. The subpopulation of patients with
CM +MO showed a trend to a reduction in the AP/EAP
ratio during the attack with respect to the interictal
period (2.2 ± 1.2 vs 3.4 ± 1.8, respectively; p = 0.06).
No significant associations were found between plasma
neurosteroid levels and BDI, SAS, HIT-6 or MIDAS
scores. In addition, there was no association between
neurosteroids and education level in our patients.
Cluster headache
Patients affected by CH showed lower levels of AP and
no changes in other neurosteroids with respect to
healthy controls (Table 6). The reduction in AP levels
was maintained when blood samples were collected dur-
ing or between headache attacks (0.4 ± 0.1 ng/mL; n = 6,
p < 0.05 vs controls during attacks, and 0.3 ± 0.1 ng/mL;
n = 12, vs the same controls, p < 0.05 in the interictal
period). The other neurosteroids did not change during
or between headache attacks.
No significant associations were found between neuro-
steroids and BDI, SAS or HIT-6 scores or education
level also in patients affected by CH.
Discussion
Our findings suggest that changes in neurosteroid levels
contribute to the pathophysiology of migraine and
cluster headache, with the obvious limitation that plasma
levels may not entirely reflect CNS levels. We found ele-
vated AP levels and reduced DHEA levels in all patients
affected by migraine, whereas EAP levels were increased
Table 1 Demographic and clinical characteristics of the recruited patients affected by episodic migraine, chronic migraine, or cluster
headache, and their respective healthy controls
Episodic migraine Chronic migrainea Controls (female) Cluster headache Controls (male)
n. 19 51 31 18 16
Age (years) 41,6±16,2 51,6±10,9 52,1±17,8 46,2±15,8 58,7±13,8
Menopause 36% (7/19) 62% (32/51) 54% (17/31) N.A. N.A.
Sampling during migraine/headache attack 0% 53% N.A. 39% N.A.
BDI (n.)
no/mild/mod./severe
18
12/4/2
49
26/11/7/5
N.A. 18
14/3/0/1
N.A.
SAS (n.)
low/moderate/severe
17
14/3/0
48
27/18/3
N.A. 18
16/2/0
N.A.
HIT-6 (n.)
mild/mod./relevant/severe
18
5/0/0/13
49
1/2/2/44
N.A. 18
2/5/3/8
N.A.
MIDAS (n.)
I→IV (low→severe disability)
18
2/4/5/7
49
4/5/3/37
N.A. N.A. N.A.
aincluding chronic migraine and medication-overuse headache patients
Table 2 Plasma neurosteroid levels in patients affected by
episodic migraine patients and healthy controls
Episodic migraine Controls P
AP (ng/mL) 1.3 ± 0.5 0.6 ± 0.3 < 0.01
EAP (ng/mL) 0.7 ± 0.2 0.4 ± 0.1 < 0.01
DHEA (ng/mL) 2.9 ± 1.5 5.1 ± 3.8 < 0.05
DHEAS (μg/mL) 2.4 ± 1.1 2.7 ± 2.0 n.s.
Values are means + S.D. Statistical analysis was performed by Student’s t test
Table 3 Plasma neurosteroid levels in patients affected by
chronic migraine patients and healthy controls
Chronic migraine
(overall population)
Controls P
AP (ng/mL) 1.1 ± 0.3 0.61 ± 0.3 < 0.01
EAP (ng/mL) 0.4 ± 0.2 0.41 ± 01 n.s.
DHEA (ng/mL) 1.6 ± 1.1 5.1 ± 3.8 < 0.01
DHEAS (μg/mL) 1.2 ± 0.9 2.76 ± 2.0 < 0.01
Values are means + S.D. Statistical analysis was performed by Student’s t test
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only in patients affected by EM, and DHEAS levels were
reduced only in patients affected by CM. It is generally
believed that abnormalities in the regulation of neuronal
excitability underlie the pathophysiology of migraine,
giving raise to cortical spreading depression or to
functional changes in pain regulatory centers of the
brainstem [21]. Neurosteroids play a key role in the regu-
lation of neuronal excitability by modulating the activity
of γ-aminobutyric acid A and N-methyl-d-aspartate recep-
tors [5], with AP behaving as a positive allosteric modula-
tor of both synaptic and extrasynaptic γ-aminobutyric
acid A receptors by interacting with a picrotoxin-sensitive
site localized within the γ-aminobutyric acid A -gated
chloride channel [22, 23]. Activation of γ-aminobutyric
acid A receptors restrains synaptic excitation, and, there-
fore, the increase in AP found in EM and CM patients
might be considered as a defensive mechanism aimed at
limiting the enhanced neuronal excitability associated with
migraine. This putative defensive mechanism might also
involve γ-aminobutyric acid A receptors localized outside
the blood-brain barrier. Accordingly, Moskowitz et al.
have found that systemic injection of progesterone, AP,
and other γ-aminobutyric acid-mimetic neurosteroids
inhibits neurogenic edema in the rat meninges, and this
effect is blocked by bicuculline, a γ-aminobutyric acid A
receptor antagonist that is unable to cross the blood-brain
barrier [24]. The reduction in DHEA (in EM and CM
patients) and DHEAS (only in CM patients) levels might
contribute to restrain neuronal excitation and neurogenic
edema because both steroids behave as weak negative allo-
steric modulators or γ-aminobutyric acid A receptors [7].
Interestingly, and counterintuitively, the drop in DHEA
and DHEAS levels was more substantial in CM patients,
suggesting that adaptive mechanisms that reinforce
γ-aminobutyric acid mediated transmission are more
prominent in CM with respect to EM. Accordingly, only
EM patients showed increases in the levels of EAP, a
neurosteroid that is devoid of intrinsic efficacy and
behaves as competitive antagonist at the AP site of
γ-aminobutyric acid A receptors [20]. Perhaps, it is a high
recurrence of migraneous attacks that drives the large
reductions in DHEA and DHEAS (associated with the
increase in AP) as an extreme but unsuccessful attempt to
reinforce γ-aminobutyric acid mediated transmission. In
contrast, even a lower reduction in DHEA levels (always
associated with the increase in AP levels) might be suffi-
cient to restrain migraneous episodes in patients affected
by EM. Interestingly, patients affected by CM+MO
showed reduced AP levels and AP/EAP ratio during the
migraneous attack, whereas the remaining CM patients
showed increases in DHEAS levels during the attack.
These findings suggest that either changes in neurosteroid
levels are causally related to the onset of the migraneous
attack, or, alternatively, is the attack itself that causes
alterations in neurosteroid levels. We favour the former
hypothesis because a reduction in AP levels (in CM+MO
patients) and an increase in DHEAS levels (in non-CM+
MO patients) should restrain synaptic inhibition. Longitu-
dinal studies in patients are necessary to establish whether
measurements of plasma neurosteroids may help to
predict the transition from EM to CM.
A different scenario was observed in patients affected
by CH, in which AP levels were largely reduced, and not
increased as observed in EM or CM patients. This
suggests that changes in neurosteroid levels in CH are
not “defensive”, but might contribute to the pathophysi-
ology of CH, lending credit to the hypothesis that mi-
graine and CH are different disease, yet sharing an
increased neuronal excitability as a common patho-
physiological substrate. The reduction of AP levels could
also help to explain the more severe and disabling
clinical phenotype of CH, as compared to migraine. Pro-
gesterone is a metabolic precursor of both AP and
testosterone, and testosterone levels are known to be re-
duced in CH [9]. No data are available on changes in
Table 4 Comparative analysis of DHEA, DHEAS, and AP levels in
patients affected by episodic or chronic migraine
Episodic migraine
(n = 19)
Chronic migraine
(n = 51)
P
DHEA (ng/mL) 2.9 ± 1.5 1.6 ± 1.1 < 0.01
DHEAS (μg/mL) 2.4 ± 1.1 1.2 ± 0.9 < 0.01
AP (ng/mL) 1.3 ± 0.5 1.1 ± 0.3 n.s.
Values are means + SD. Statistical analysis was performed by Student’s t test
Table 5 Plasma neurosteroid levels in the overall population of
patients affected by chronic migraine during the headache
attack and in the interictal period
Chronic migraine
during attack (n = 27)
Chronic migraine
no attack (n = 24)
Controls
AP (ng/mL) 1.1 ± 0.4* 1.1 ± 0.2* 0.6 ± 0.3
EAP (ng/mL) 0.5 ± 0.1 0.4 ± 0.2 0.4 ± 0.1
DHEA (ng/mL) 1.4 ± 0.9* 1.8 ± 1.2* 5.1 ± 3.8
DHEAS (μg/mL) 1.5 ± 1.1* 1.0 ± 0.6* 2.7 ± 2.0
Values are means + S.D. *p<0.05 vs. the respective control groups. No
significant changes were found between values obtained during the attack
and in the interictal period. Statistical analysis was performed by One-way
ANOVA + Fisher’s LSD (AP, F2,79 = 24.79; EAP, F2,79 = 1.43; DHEA, F2,79 = 18.06;
DHEAS, F2,79 = 10.66)
Table 6 Plasma neurosteroid levels in patients affected by
cluster headache and their healthy controls
Cluster headache Controls P
AP (ng/mL) 0.3 ± 0.1 0.7 ± 0.2 < 0.01
EAP (ng/mL) 0.4 ± 0.1 0.3 ± 0.2 n.s.
DHEA (ng/mL) 2.9 ± 2.2 4.3 ± 5.0 n.s.
DHEAS (μg/mL) 2.6 ± 1.7 2.2 ± 1.7 n.s.
Values are means + S.D. Statistical analysis was performed by Student’s t test
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progesterone levels in CH because the disorder is highly
prevalent in males. Perhaps there is a primary reduction
in progesterone levels in CH, which results into a
secondary drop in both AP and testosterone levels. This
interesting hypothesis warrants further investigation.
Conclusion
In conclusion, we have shown for the first time that large
and disease-specific changes in circulating neurosteroid
levels are associated with chronic headache disorders, rais-
ing the interesting possibility that fluctuations of neuro-
steroids at their site of action might shape the natural
course of migraine and CH. Whether the observed changes
in neurosteroids are genetically determined or rather result
from exposure to environmental or intrinsic stressors [25]
is unknown. This might also be matter for further investiga-
tion because stress is a known triggering factor for head-
ache attacks in both migraineurs and CH patients.
In the future, it will be interesting to verify also the
correlations between specific comorbidities presenting
similar neural hyperexcitability of migraine, like fibro-
myalgia [26], or correlate the neuroinflammation related
to dyslipidemia in migraine [27].
Last, our findings may lay the groundwork for novel
neurosteroid-based therapeutic strategies in the
treatment chronic headache disorders. Ganaxolone, a
synthetic γ-aminobutyric acid-mimetic analogue of AP,
has been developed for the treatment of epilepsy, and it
showed good efficacy and safety profile in patients with
uncontrolled focal seizures in a phase-II placebo con-
trolled clinical trial [28]. Our data encourage the experi-
mental use of ganoxolone particularly in CH patients,
where AP levels were found to be largely reduced.
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